Page 62 - AN-4-4

Advanced Neurology Covert cerebral small vessel disease

26. Skitek M, Jerin A. N-methyl-D-aspartate-receptor 36. Li Y, Sun Y, Li J, et al. Changes of ubiquitin C-terminal
antibodies, s100b protein, and neuron-specific enolase hydrolase-L1 levels in serum and urine of patients with
before and after cardiac surgery: Association with ischemic white matter lesions. J Neurol Sci. 2015;357:215-221.
brain injury and erythropoetin prophylaxis. Lab Med. doi: 10.1016/j.jns.2015.07.033
2013;44(1):56-62.
37. Janelidze S, Stomrudm E, Palmqvist S, et al. Plasma
doi: 10.1309/LMZI8CEAATHRXR74 β-amyloid in Alzheimer’s disease and vascular disease. Sci
27. Yoneda K, Hosomi S, Ito H, et al. How can heatstroke Rep. 2016;6:26801.
damage the brain? A mini review. Front Neurosci. 2024; doi: 10.1038/srep26801
18:1437216.
38. González-Quevedo A, González-García S, Hernández-
doi: 10.3389/fnins.2024.1437216 Díaz Z, et al. Serum neuron specific enolase could predict
28. Sigström R, Göteson A, Joas E, et al. Blood biomarkers of subclinical brain damage and the subsequent occurrence of
neuronal injury and astrocytic reactivity in electroconvulsive brain related vascular events during follow up in essential
therapy. Mol Psychiatry. 2024. hypertension. J Neurol Sci. 2016;363:158-163.
doi: 10.1038/s41380-024-02774-4 doi: 10.1016/j.jns.2016.02.052
29. Cooper J, Stukas S, Hoiland RL, et al. Quantification 39. González-García S, González-Quevedo A, Hernandez-Diaz Z,
of neurological blood-based biomarkers in critically Ill et al. Circulating autoantibodies against the NR2 peptide
patients with coronavirus disease 2019. Crit Care Explor. of the NMDA receptor are associated with subclinical
2020;2(10):e0238. brain damage in hypertensive patients with other pre-
existing conditions for vascular risk. J Neurol Sci. 2017;375:
doi: 10.1097/CCE.0000000000000238 324-330.
30. Zonner S, Ejima K, Bevilacqua Z, et al. Association of doi: 10.1016/j.jns.2017.02.028
increased serum S100B Levels with high school football
subconcussive head impacts. Front Neurol. 2019;10:327. 40. Duering M, Konieczny M, Tiedt S, et al. Serum neurofilament
light chain levels are related to small vessel disease burden.
doi: 10.3389/fneur.2019.00327 J Stroke. 2018;20(2):228-238.
31. Dambinova S, Maroon J, Sufrinko A, Mullins J, Alexandrova E, doi: 10.5853/jos.2017.02565
Potapov A. Functional, structural, and neurotoxicity 41. Van Leijsen E, Kuiperij H, Kersten I, et al. Plasma Aβ
biomarkers in integrative assessment of concussions. Front (Amyloid-β) levels and severity and progression of small
Neurol. 2016;7:172.
vessel disease. Stroke. 2018;49(4):884-890.
doi: 10.3389/fneur.2016.00172
doi: 10.1161/STROKEAHA.117.019810
32. Kobeissy F, Moshourab R. Autoantibodies in CNS trauma 42. Dobrynina LA, Alexandrova EV, Zabitova MR,
and neuropsychiatric disorders: A new generation of Kalashnikova LA, Krotenkova MV, Akhmetzyanov BM.
biomarkers. In: Kobeissy F, editor. Brain Neurotrauma: Anti-NR2 glutamate receptor antibodies as an early
Molecular, Neuropsychological, and Rehabilitation Aspects. biomarker of cerebral small vessel disease. Clin Biochem.
Boca Raton, FL: CRC Press, Taylor & Francis; 2015. 2021;96:26-32.
33. Gonzalez-Quevedo A, González García S, Fernández doi: 10.1016/j.clinbiochem.2021.07.003
Concepción O, et al. Increased serum S-100B and neuron
specific enolase - potential markers of early nervous system 43. Fohner AE, Bartz TM, Tracy RP, et al. Association of serum
involvement in essential hypertension. Clin Biochem. neurofilament light chain concentration and MRI findings
2011;44(2-3):154-159. in older adults: the cardiovascular health study. Neurology.
2022;98(9):e903-e911.
doi: 10.1016/j.clinbiochem.2010.11.006
doi: 10.1212/WNL.0000000000013229
34. Kaffashian S, Tzourio C, Soumaré A, et al. Plasma β-amyloid
and MRI markers of cerebral small vessel disease: Three-city 44. Ottavi TP, Pepper E, Bateman G, Fiorentino M, Brodtmann A.
Dijon study. Neurology. 2014;83(22):2038-2045. Consensus statement for the management of incidentally
found brain white matter hyperintensities in general medical
doi: 10.1212/WNL.0000000000001038 practice. Med J Aust. 2023;219(6):278-284.
35. Gao Q, Fan Y, Mu LY, Ma L, Song ZQ, Zhang YN. S100B doi: 10.5694/mja2.52079
and ADMA in cerebral small vessel disease and cognitive 45. Wardlaw JM, Woodhouse LJ, Mhlanga II, et al. Isosorbide
dysfunction. J Neurol Sci. 2015;354:27-32.
mononitrate and cilostazol treatment in patients with
doi: 10.1016/j.jns.2015.04.031 symptomatic cerebral small vessel disease: The lacunar

Volume 4 Issue 4 (2025) 56 doi: 10.36922/an.4841